FDA approval coincides with flat GSK stock price as sellers maintain pressure
GSK (GSK) stock is trading at GBX1,871 after an unchanged session, with no movement reported for the day. The price remains positioned below its key moving averages, suggesting an ongoing period of technical pressure.
Highlights
- The FDA granted accelerated approval for GSK's lung cancer drug neladalkib, to be marketed as Nelkarmi.
- This approval follows GSK's $10.6 billion acquisition of Nuvalent in July 2026, expanding its oncology portfolio.
- Shares of GSK/GBX trade below key moving averages with momentum indicators showing seller control and a projected range of GBX1,835 to GBX1,906.
Oncology outlook improves after FDA grants early drug approval
The U.S. FDA granted accelerated approval for GSK's lung cancer drug neladalkib, to be sold as Nelkarmi, according to Investing.com. This milestone follows GSK's $10.6 billion acquisition of Nuvalent in July 2026, securing rights to the new therapy. The regulatory approval enables earlier market entry and enhances the company's long-term outlook within the oncology segment.
Sustained selling pressure as price remains below key resistance
On the technical front, GSK is trading below the H1 SMA-20 at GBX1,912 and the H1 SMA-50 at GBX1,909, as well as beneath the D1 SMA-200 at GBX1,954. The Ichimoku Kijun is set at GBX1,909 and represents immediate resistance. Momentum indicators remain weak, with MACD and ADX pointing to ongoing selling pressure. On the H1 timeframe, RSI, Stoch RSI, and CCI are all in oversold territory, while Bull/Bear Power is marked at -20.14, confirming clear intraday dominance by sellers.
Downside risk elevated amid skewed probability to further declines
Looking ahead, GSK is expected to trade within a typical volatility band between GBX1,835 and GBX1,906 over the next several sessions. There is a 22% probability of the price moving higher and a 78% probability of a further decline, indicating downside continuation as the more likely scenario. The baseline view is for the price to remain in a sideways corridor unless there is a confirmed breakout above resistance or a breakdown below support.
Previously it was reported that GSK received U.S. regulatory approval for its new lung cancer therapy, bolstering its oncology pipeline following the Nuvalent acquisition. Despite this development, technical indicators suggest sustained downside risk prevails, making a breakdown below GBX1,835 a key level for traders to monitor in the near term.